2025-06-16 • ScienceDaily Psychedelics

Single psilocybin trip delivers two years of depression relief for cancer patients

Psilocybin, the active ingredient in magic mushrooms, might just revolutionize how depression and anxiety are treated in cancer patients. In a groundbreaking trial, a single dose combined with therapy significantly reduced emotional suffering, and these effects often lasted over two years. As follow-up studies expand the research to multiple doses and larger samples, scientists are eyeing a possible new standard of care that merges psychedelics with psychological support.

External link. We are not responsible for the content.

Read more ↗

More From ScienceDaily Psychedelics

2026-02-15 • ScienceDaily Psychedelics

Psychedelics may work by shutting down reality and unlocking memory

Psychedelics can quiet the brain’s visual input system, pushing it to replace missing details with vivid fragments fr...

2025-10-28 • ScienceDaily Psychedelics

Scientists discover a surprising way to quiet the anxious mind

Generalized anxiety disorder affects millions, often trapping sufferers in cycles of fear and isolation that conventi...

2025-10-02 • ScienceDaily Psychedelics

A single dose of psilocybin may rewire the brain for lasting relief

Penn researchers found that psilocybin can calm brain circuits tied to pain and mood, easing both physical suffering ...

Latest News

2026-02-28 • Chemical Collective

Comment perfectionner la préparation de son trip ?

La préparation d’un voyage est un processus à la fois intérieur et extérieur – qui consiste à aligner l’intention, l’...

2026-02-27 • Lucid News

Authors of Largest Microdosing Study Suggest Benefits Limited To Dosing Day

Recent research surveying 1,435 microdosers suggests that microdosing’s duration of effect might be more like that of...

Microdosing Research
2026-02-27 • The Microdose (Berkeley)

The FDA is changing the drug approval process; In a Senate hearing, Surgeon General nominee Casey Means was asked about psychedelics use

Plus: RAND survey shows that nearly a quarter of U.S. adults support legal use of psilocybin mushrooms; Reunion Neuro...

2026-02-27 • Psychedelic Alpha

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

In this conversation with Psychedelic Alpha’s Josh Hardman, Dr. Terence Ching discusses his journey into the field an...

2026-02-27 • Tripsitter (Substack)

Can Psychedelics Break the Consumption Cycle?

Consumer culture doesn’t just shape what we buy — it shapes what we want. Here’s why that’s harder to escape than you...

2026-02-27 • The Psychedelic Blog (Substack)

Psychedelics Can Just Be for Fun

Welcome to the Psychedelic Blog. I write about the impact of Psychedelics on Grieving, Relationships, Culture & Death.